Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Gastrointestinal infection and idiopathic Parkinsonism

Categorization the presence or absence of Helicobacter infection, is a useful therapeutic tool in idiopathic parkinsonism, and interim analysis points to a role of a particular infection in the pathogenesis, reports two studies in the latest issue of Helicobacter.

News image

fiogf49gjkf04

Neuronal damage in idiopathic parkinsonism may be in response to ubiquitous occult infection.

Since peptic ulceration is prodromal, Helicobacter is a prime candidate.

Dr John Dobbs and colleagues considered the candidature of Helicobacter in parkinsonism with cachexia.

The researchers explored the relationship between being underweight and inflammatory products in 124 subjects with idiopathic parkinsonism and 195 controls.

The team presented case-series evidence of efficacy of H pylori eradication, in parkinsonism advanced to the stage of cachexia for the first part of their study.

The team also obtained proof-of-principle that infection contributes to idiopathic parkinsonism.

An association of a low body mass index with circulating interleukin-6 that was specific to parkinsonism
Helicobacter

For the second part of the researcher's investigation, the team conducted a randomized, double-blind, placebo-controlled efficacy study.

The researchers considered proven Helicobacter pylori eradication on the time course of facets of parkinsonism.

Intervention was 1 week's triple eradication therapy versus placebos.

For Study 1, the team found an association of a low body mass index with circulating interleukin-6 that was specific to parkinsonism.

Marked reversibility in both cachexia and disability of idiopathic parkinsonism followed Helicobacter heilmannii eradication in 1 case.

The team noted that, H pylori eradication in another case presented with postprandial bloating, and persistent nausea.

The researchers found that, following eradication, radioisotope gastric-emptying returned towards normal, and upper abdominal symptoms regressed.

Reversibility of their cachexia contrasts with the outcome of anti-Helicobacter therapy, where eradication failed in 1 case, and in non-Helicobacter gastritis in 3 cases.

The researchers noted that in Study 1, anti-parkinsonian medication remained constant.

Intestinal absorption and barrier function were normal in all.

In the second study, the team noted active vs placebo improvements in stride-length.

The improvement exceeded size of effect on which the sample size was calculated when analyzed on intention-to-treat basis.

The researchers also observed an improvement on protocol analysis of 6 weekly assessments, including and excluding those on antiparkinsonian medication.

Active eradication failed in 4 out of 20 patient , in whom B-lymphocyte count was lower.

Dr Dobbs' team concludes, “Categorization, according to presence or absence of Helicobacter infection, was a useful therapeutic tool in late idiopathic parkinsonism.”

“In the second study, interim analysis points to a direct or surrogate role of a particular infection in the pathogenesis of parkinsonism.”

“With eradication failure, bolus release of antigen from killed bacteria could aggravate an effect of ongoing infection.”

Helicobacter 2005: 10(4): 267
11 August 2005

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us